Jove
Visualize
Contact Us

Related Concept Videos

Drug Biotransformation: Overview01:16

Drug Biotransformation: Overview

4.1K
Pharmaceutical substances known as xenobiotics are predominantly lipophilic and nonionized. This enables them to permeate lipid bilayers, such as cell membranes, and interact with intracellular target receptors. Lipophilic drugs have an advantage in crossing biological barriers and reaching their intended sites of action. However, lipophilic drugs often have a restricted capacity for renal expulsion or elimination from the body. When these drugs enter the kidneys and undergo glomerular...
4.1K
Drug Biotransformation: Overview01:28

Drug Biotransformation: Overview

5.2K
Biotransformation, also known as drug metabolism, is a vital physiological process that chemically alters drugs, facilitating their elimination from the body and terminating their action. This process involves two main phases: phase I and phase II reactions. Phase I reactions, including oxidation, reduction, and hydrolysis, introduce or unmask polar functional groups on the drug molecule, thereby increasing its water solubility. By enhancing water solubility, the drug becomes more hydrophilic...
5.2K
Drug Metabolism: Phase II Reactions01:14

Drug Metabolism: Phase II Reactions

5.5K
Phase II reactions are essential for the detoxification and elimination of drugs from the body. These reactions involve the conjugation of parent drugs or their phase I metabolites with endogenous molecules, resulting in more hydrophilic drug conjugates. The primary conjugation reactions in this phase are sulfation and glucuronidation. Both sulfation and glucuronidation typically produce biologically inactive metabolites. However, in some cases involving prodrugs, active metabolites may be...
5.5K
Pharmacogenetics of Phase II Enzymes: N-acetyltransferase, Thiopurine S-methyltransferase, UDP-glucuronosyltransferase01:27

Pharmacogenetics of Phase II Enzymes: N-acetyltransferase, Thiopurine S-methyltransferase, UDP-glucuronosyltransferase

57
Phase II biotransformation reactions are essential for detoxifying and eliminating xenobiotics, including many pharmaceutical compounds. These reactions typically involve conjugation, the covalent attachment of polar endogenous groups such as glucuronic acid, sulfate, methyl, or acetyl moieties to functional groups introduced during Phase I metabolism. The resulting conjugates are more water-soluble, enabling efficient renal or biliary excretion.The major classes of Phase II enzymes include...
57
Phase II Reactions: Sulfation and Conjugation with α-Amino Acids01:19

Phase II Reactions: Sulfation and Conjugation with α-Amino Acids

1.2K
Sulfation and α-amino acid conjugation are two critical biotransformation reactions in drug metabolism. Sulfation, a phase II biotransformation reaction, involves adding a polar sulfate group to a drug, enhancing its water solubility and promoting excretion. This process can either co-occur with or occur independently of glucuronidation. Nonmicrosomal sulfotransferase enzymes catalyze the process. The reaction involves 3'-phosphoadenosine-5'-phosphosulfate or PAPS coenzyme...
1.2K
Preparation of 1° Amines: Hofmann and Curtius Rearrangement Overview01:07

Preparation of 1° Amines: Hofmann and Curtius Rearrangement Overview

3.9K
In the presence of an aqueous base and a halogen, primary amides can lose the carbonyl (as carbon dioxide) and undergo rearrangement to form primary amines. This reaction, called the Hofmann rearrangement, can produce primary amines (aryl and alkyl) in high yields without contamination by secondary and tertiary amines.
3.9K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Identification and validation of genes encoding humoral specificity for the chemical allergen toluene diisocyanate.

PloS one·2026
Same author

Phase 1 study of zavondemstat (TACH101), a first-in-class KDM4 inhibitor, in patients with advanced solid tumors.

The oncologist·2025
Same author

Phase 1 study of HP518, a PROTAC AR degrader in patients with mCRPC: results on safety, pharmacokinetics, and anti-tumor activity.

Investigational new drugs·2025
Same author

Lung Gene Expression Suggests Roles for Interferon-Stimulated Genes and Adenosine Deaminase Acting against RNA-1 in Pathologic Responses to Diisocyanate.

Chemical research in toxicology·2024
Same author

Occupational Risk Factors for SARS-CoV-2 Seropositivity in Healthcare Workers: Results of a Longitudinal Cohort.

Journal of occupational and environmental medicine·2023
Same author

Changes Over Time in COVID-19 Incidence, Vaccinations, Serum Spike IgG, and Viral Neutralizing Potential Among Individuals From a North American Gaming Venue: December 2020-August 2021.

Journal of occupational and environmental medicine·2022
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Video

Updated: Mar 19, 2026

Chemical Inactivation of the E3 Ubiquitin Ligase Cereblon by Pomalidomide-based Homo-PROTACs
10:44

Chemical Inactivation of the E3 Ubiquitin Ligase Cereblon by Pomalidomide-based Homo-PROTACs

Published on: May 15, 2019

13.9K

Biotransformation and Rearrangement of Laromustine.

Alaa-Eldin F Nassar1, Adam V Wisnewski2, Ivan King2

  • 1Department of Internal Medicine, School of Medicine, Yale University, New Haven, Connecticut (A.-E.F.N., A.V.W.); Department of Chemistry, University of Connecticut, Storrs, Connecticut (A.-E.F.N.); Metastagen, Inc., Wilmington, Delaware (I.K.) ala.nassar@yale.edu.

Drug Metabolism and Disposition: the Biological Fate of Chemicals
|June 10, 2016
PubMed
Summary

Laromustine undergoes decomposition and hydrolysis in liver microsomes, with limited species variation. Cytochrome P450 enzymes are minimally involved, suggesting reactive intermediates may cause toxicity.

More Related Videos

A Method for Screening and Validation of Resistant Mutations Against Kinase Inhibitors
12:40

A Method for Screening and Validation of Resistant Mutations Against Kinase Inhibitors

Published on: December 7, 2014

15.3K
Utilizing 18F-FDG PET/CT Imaging and Quantitative Histology to Measure Dynamic Changes in the Glucose Metabolism in Mouse Models of Lung Cancer
06:51

Utilizing 18F-FDG PET/CT Imaging and Quantitative Histology to Measure Dynamic Changes in the Glucose Metabolism in Mouse Models of Lung Cancer

Published on: July 21, 2018

18.8K

Related Experiment Videos

Last Updated: Mar 19, 2026

Chemical Inactivation of the E3 Ubiquitin Ligase Cereblon by Pomalidomide-based Homo-PROTACs
10:44

Chemical Inactivation of the E3 Ubiquitin Ligase Cereblon by Pomalidomide-based Homo-PROTACs

Published on: May 15, 2019

13.9K
A Method for Screening and Validation of Resistant Mutations Against Kinase Inhibitors
12:40

A Method for Screening and Validation of Resistant Mutations Against Kinase Inhibitors

Published on: December 7, 2014

15.3K
Utilizing 18F-FDG PET/CT Imaging and Quantitative Histology to Measure Dynamic Changes in the Glucose Metabolism in Mouse Models of Lung Cancer
06:51

Utilizing 18F-FDG PET/CT Imaging and Quantitative Histology to Measure Dynamic Changes in the Glucose Metabolism in Mouse Models of Lung Cancer

Published on: July 21, 2018

18.8K

Area of Science:

  • Pharmacology and Toxicology
  • Drug Metabolism
  • Analytical Chemistry

Background:

  • Laromustine is a sulfonylhydrazine-alkylating agent investigated for its therapeutic potential.
  • Understanding the biotransformation and rearrangement pathways of laromustine is crucial for assessing its safety and efficacy.
  • Previous studies have suggested potential toxicities associated with laromustine in clinical trials.

Purpose of the Study:

  • To elucidate the biotransformation and rearrangement pathways of laromustine in various animal and human liver microsomes.
  • To identify the metabolites and decomposition products of laromustine.
  • To investigate the role of specific enzymes, such as Cytochrome P450, in laromustine metabolism.

Main Methods:

  • Incubation of [(14)C]laromustine with rat, dog, monkey, and human liver microsomes.
  • Liquid chromatography-multistage mass spectrometry (LC-MS(n)) for metabolite identification and structural elucidation.
  • Fourier-transform ion cyclotron resonance mass spectrometry (FTICR-MS) for accurate mass measurements and elemental composition determination.
  • Hydrogen-deuterium exchange, (13)C-labeled laromustine, and nuclear magnetic resonance (NMR) spectroscopy for detailed mechanistic studies.

Main Results:

  • Eight radioactive components (C-1 to C-8) were identified, with minimal species-dependent differences in metabolite profiles.
  • Most metabolites were formed via decomposition and/or hydrolysis, independent of NADPH.
  • A hydroxylated metabolite (C-7) was identified, primarily formed by CYP2B6 and CYP3A4/5.
  • Collision-induced dissociation, not biotransformation, generated a unique mass spectral rearrangement involving loss of N2, methylsulfonyl, and methyl isocyanate.
  • Laromustine generates reactive intermediates potentially responsible for observed clinical toxicities.

Conclusions:

  • Laromustine metabolism is largely independent of species and NADPH, primarily involving decomposition and hydrolysis.
  • Cytochrome P450 enzymes play a minor role in laromustine biotransformation, except for the formation of the C-7 metabolite.
  • The identified reactive intermediates suggest a mechanism for laromustine-induced toxicity observed in clinical settings.